CMIC Group
Contract research, development and manufacturing organization providing end-to-end services across preclinical, clinical, regulatory, manufacturing and commercial stages. Offers CRO, CDMO, bioanalysis, regulatory consulting, pharmacovigilance, real-world evidence and digital health solutions with operational focus in Japan and the wider Asia-Pacific region.
Industries
Nr. of Employees
large (251-1000)
CMIC Group
Hoffman Estates, Illinois, United States, North America
Products
Cloud vaccination information management system
Cloud-based system for recording vaccination details, scheduling and follow-up alerts to support mass vaccination programs.
Cloud vaccination information management system
Cloud-based system for recording vaccination details, scheduling and follow-up alerts to support mass vaccination programs.
Services
End-to-end clinical trial services including protocol development, project management, site management, monitoring and patient recruitment with APAC coverage.
Local operational oversight, regulatory liaison and investigator engagement for sponsors conducting trials in Japan and other APAC countries; fulfils in-country caretaker regulatory responsibilities.
Site network and medical-concierge services providing coverage and engagement across a large network of medical institutions in Japan to support site selection, activation and site liaison.
GLP/nonclinical study execution, toxicology/safety pharmacology and regulated bioanalytical testing for small and large molecules.
Formulation, process development, clinical batch manufacturing, technology transfer, CMC documentation and commercial manufacturing including sterile/parenteral and oral dosage forms.
Regulatory submissions, market feasibility, designation pathway support and local market-entry strategy for Japan and APAC.
End-to-end clinical trial services including protocol development, project management, site management, monitoring and patient recruitment with APAC coverage.
Local operational oversight, regulatory liaison and investigator engagement for sponsors conducting trials in Japan and other APAC countries; fulfils in-country caretaker regulatory responsibilities.
Site network and medical-concierge services providing coverage and engagement across a large network of medical institutions in Japan to support site selection, activation and site liaison.
GLP/nonclinical study execution, toxicology/safety pharmacology and regulated bioanalytical testing for small and large molecules.
Formulation, process development, clinical batch manufacturing, technology transfer, CMC documentation and commercial manufacturing including sterile/parenteral and oral dosage forms.
Regulatory submissions, market feasibility, designation pathway support and local market-entry strategy for Japan and APAC.
Expertise Areas
- Clinical trial management (Phase I–IV) in APAC
- In-country site operations and ICCC responsibilities
- Clinical site network and site-management (SMO) services in Japan
- Decentralized, hybrid and virtual trial models
Key Technologies
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- Lipidomics by LC-MS
- PK and ADA immunoassays
- Oligonucleotide assay development
News & Updates
White paper describing trends and operational considerations for decentralized clinical trials in Japan.
Global CRO Council recommendations and interpretation of EMA guidance on bioanalytical method validation.
Webinar on mRNA therapeutic approaches, preclinical considerations and development prospects.
Video discussion of Japan market environment, regulatory strategies and market entry considerations.
Recorded session covering regulatory framework, initial regulatory steps and clinical development considerations for cell and gene therapies in Japan.
Webinar on market dynamics, regulatory differences and strategies for clinical development in Japan and China, including HEOR and quality perspectives.
White paper describing trends and operational considerations for decentralized clinical trials in Japan.
Global CRO Council recommendations and interpretation of EMA guidance on bioanalytical method validation.
Webinar on mRNA therapeutic approaches, preclinical considerations and development prospects.
Video discussion of Japan market environment, regulatory strategies and market entry considerations.
Recorded session covering regulatory framework, initial regulatory steps and clinical development considerations for cell and gene therapies in Japan.
Webinar on market dynamics, regulatory differences and strategies for clinical development in Japan and China, including HEOR and quality perspectives.